Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART-LM: Proton Craniospinal Irradiation vs Intrathecal Pemetrexed for NSCLC Leptomeningeal Metastasis
NCT07751536Recruiting
- Sponsor
- Shuanghu Capital
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of pemetrexed in leptomeningeal metastasis (LM) (2 cohorts), sponsored by Shuanghu Capital. Primary endpoint: Intracranial progression-free survival up to 2 years. Started Aug 2026; status: recruiting.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT07751536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751536.